BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

817 related articles for article (PubMed ID: 32563654)

  • 1. Diagnostic Accuracy of Cardiac Computed Tomography and 18-F Fluorodeoxyglucose Positron Emission Tomography in Cardiac Masses.
    D'Angelo EC; Paolisso P; Vitale G; Foà A; Bergamaschi L; Magnani I; Saturi G; Rinaldi A; Toniolo S; Renzulli M; Attinà D; Lovato L; Lima GM; Bonfiglioli R; Fanti S; Leone O; Saponara M; Pantaleo MA; Rucci P; Di Marco L; Pacini D; Pizzi C; Galiè N
    JACC Cardiovasc Imaging; 2020 Nov; 13(11):2400-2411. PubMed ID: 32563654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving the imaging diagnostic strategy for pulmonary artery masses based on
    Hong C; Hou P; Chen HM; Zhong KX; Guo WL; Lin JL; Wu XF; Lei YX; Jia Q; Liu CL; Li SY; Wang XL
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4109-4121. PubMed ID: 35732973
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Qin C; Shao F; Hu F; Song W; Song Y; Guo J; Lan X
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1083-1093. PubMed ID: 31807883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical value of texture analysis of dual-time-point
    Nakajo M; Jinguji M; Aoki M; Tani A; Sato M; Yoshiura T
    Eur Radiol; 2020 Mar; 30(3):1759-1769. PubMed ID: 31728684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of focal hypermetabolic thyroid incidentaloma: An analysis with F-18 fluorodeoxyglucose positron emission tomography/computed tomography parameters.
    Lee H; Chung YS; Lee JH; Lee KY; Hwang KH
    World J Clin Cases; 2022 Jan; 10(1):155-165. PubMed ID: 35071515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiating benign and malignant pancreatic masses: Ga-68 PSMA PET/CT as a new diagnostic avenue.
    Krishnaraju VS; Kumar R; Mittal BR; Sharma V; Singh H; Nada R; Bal A; Rohilla M; Singh H; Rana SS
    Eur Radiol; 2021 Apr; 31(4):2199-2208. PubMed ID: 33001304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
    Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
    J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
    Ciftci E; Turgut B; Cakmakcilar A; Erturk SA
    Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of
    Dolci C; Ceppi L; Guerra L; Crivellaro C; Lamanna M; Adorni M; Elisei F; Bonazzi CM; Sina F; Fruscio R; Messa C
    Int J Gynecol Cancer; 2019 Oct; 29(8):1298-1303. PubMed ID: 31366569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The usefulness of (18)F-FDG PET/CT for assessing methotrexate-associated lymphoproliferative disorder (MTX-LPD).
    Watanabe S; Manabe O; Hirata K; Oyama-Manabe N; Hattori N; Kikuchi Y; Kobayashi K; Toyonaga T; Tamaki N
    BMC Cancer; 2016 Aug; 16():635. PubMed ID: 27528380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and staging of cardiac masses: additional value of CMR with
    Mikail N; Males L; Hyafil F; Benali K; Deschamps L; Brochet E; Ehmer C; Driss AB; Saker L; Rossi A; Alkhoder S; Raffoul R; Rouzet F; Ou P
    Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2232-2241. PubMed ID: 35247063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple metabolic parameters and visual assessment of
    Ren Y; Liu J; Wang L; Luo Y; Ding X; Shi A; Liu J
    Abdom Radiol (NY); 2020 Nov; 45(11):3569-3580. PubMed ID: 32274551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
    Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
    Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma: an Italian multicenter study.
    Quartuccio N; Evangelista L; Alongi P; Caobelli F; Altini C; Cistaro A; Lambertini A; Schiorlin I; Popescu CE; Linguanti F; Laudicella R; Scalorbi F; Di Pierro G; Asabella AN; Cuppari L; Margotti S; Lima GM; Scalisi S; Pacella S; Kokomani A; Ciaccio A; Sturiale L; Vento A; Cardile D; Baldari S; Panareo S; Fanti S; Rubini G; Schillaci O; Chiaravalloti A;
    Nucl Med Commun; 2019 Aug; 40(8):808-814. PubMed ID: 31136534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of
    Yin H; Mao W; Tan H; Zhu N; Wan Q; Shi J; Qiu L; Xiu Y; Luo R; Yu H; Shi H
    J Nucl Cardiol; 2022 Jun; 29(3):1293-1303. PubMed ID: 33462788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multimodality imaging to distinguish between benign and malignant cardiac masses.
    Aghayev A; Cheezum MK; Steigner ML; Mousavi N; Padera R; Barac A; Kwong RY; Di Carli MF; Blankstein R
    J Nucl Cardiol; 2022 Aug; 29(4):1504-1517. PubMed ID: 34476778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-time point
    Parghane RV; Basu S
    Semin Nucl Med; 2017 Jul; 47(4):373-391. PubMed ID: 28583277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.